Outsourcing: New Financial Realities Will Alter Biopharmaceutical Outsourcing Landscape - CROs and CMOs could face diminishing opportunities and escalating competition in the days ahead. - BioPharm

ADVERTISEMENT

Outsourcing: New Financial Realities Will Alter Biopharmaceutical Outsourcing Landscape
CROs and CMOs could face diminishing opportunities and escalating competition in the days ahead.


BioPharm International


BAD NEWS FOR CONTRACTORS? Big pharma's willingness to license candidates from early-stage biopharma, and even buy them outright, should preserve the flow of venture capital into the biopharmaceutical sector. While the returns on VC investments from these deals may not be as lucrative as those of IPOs, they offer another exit strategy and greater liquidity.


Service Providers in 2004
However, as more biopharmaceutical companies and their new product candidates fall under the control of big pharma, things could get rough in the contract services arena. The pool of projects that are "in play" for the broader universe of CROs and CMOs is likely to shrink as acquired development programs are moved in-house or are channeled to one of the select few preferred providers with whom major pharmaceutical companies have been consolidating their outsourcing activities.

In this scenario, hundreds of small (revenues under $50 million) CROs and CMOs will have an even harder time competing for new business. Already, preferred provider programs and acquisitions have brought about a substantial amount of consolidation in the pharmaceutical services industry. According to PharmSource estimates, the eight largest service providers already claim over 60 percent of industry capital spent in the preclinical research, clinical research, and injectables manufacturing segments of the contract services industry, and that will increase in coming years.

KEYS TO SURVIVAL The PharmSource Contractor Database lists nearly 70 providers of cell culture and fermentation manufacturing services, and another 70 fill/finish service providers in North America and Europe. Less than 10 companies in each of those segments would be considered "major" companies, i.e., large, financially-stable, brand-name companies. Most of the others are small, entrepreneurial companies with limited capital and capacity. Those companies are facing a tougher competitive environment, and many will fail.

Small CROs and CMOs that survive the shakeout will do so, in part, because of their ability to cater to profitable niches that larger companies cannot or will not serve. Discovery and early development services for early-stage companies are likely to experience strong demand as those companies become more "virtual."New financial dynamics will drive this development: venture capital firms will focus more on building attractive product portfolios, which are mostly intellectual property, and less on building companies, which require a lot of fixed assets such as buildings and equipment. Getting candidates to a proof-of-concept stage sufficient to attract a buyer or licensee can be done using contracted testing and development services.

Surviving CROs and CMOs will also be more adept in the business aspects of their operations. They will find sources of capital to fund their expansion, as Laureate Pharma, a provider of contract biomanufacturing and drug delivery services, did last year when it was acquired by Safeguard Scientifics. They will also need to become more capable at new business development, an area where they have been woefully inadequate, as they fight for a bigger share of a shrinking pie.

The shakeout of small CROs and CMOs in the biopharmaceutical services market is long overdue. The consolidation of the fragmented biopharmaceutical industry through mergers, acquisitions, and in-licensing is likely to accelerate that process.

Jim Miller is president of PharmSource Information Services, Inc., 703.914.1203, fax: 703.914.1205,
.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Yale and Gilead Extend Sequencing Initiative
October 28, 2014
Contract Research and Manufacturing Organization Paragon Bioservices Raises $13 Million
October 28, 2014
Novartis Sells Influenza Vaccine Business to CSL for $275 Million
October 27, 2014
Author Guidelines
Source: BioPharm International,
Click here